Evidence map›Paper›PMID 40454809›Full record

ArticleClinical transplantation2025

Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation.

Zaynab Somani, James S Hodges, Srinath Chinnakotla, David Martin, Karthik Ramanathan, Gregory J Beilman, Melena D Bellin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zaynab SomaniUniversity of Minnesota Medical School, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0009-0002-0261-8413
James S HodgesDivision of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-7467-6941
Srinath ChinnakotlaDivision of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-5443-1258
David MartinDivision of Critical Care & Acute Care Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Karthik RamanathanDivision of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0009-0005-7542-3969
Gregory J BeilmanDepartment of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-5036-3027
Melena D BellinDivision of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-7324-4837

Funding

NIDDK NIH HHS R01-DK126728 MDB
6 · The paper itself

Abstract

introductionTargets for continuous glucose monitoring (CGM) are well established for type 1 and type 2 diabetes. In total pancreatectomy with islet autotransplantation (TPIAT), stricter glycemic targets are needed to avoid metabolic stress on transplanted islets, but no guidelines exist for CGM targets.

methodsWe aimed to determine CGM targets for TPIAT clinical management by associating CGM metrics with goal hemoglobin A1c (HbA1c) ≤ 6.5%. Targets for time in range (TIR) 70-140, TIR 70-180, mean CGM glucose, and time in hyperglycemia (>140, >180, >250 mg/dL) were chosen to give good sensitivity and specificity for identifying HbA1c ≤6.5%.

resultsWe included 256 pairs of 14-day CGM metrics with a concurrent HbA1c value (n = 82 patients, age 35 [IQR 19-46] years at surgery, 70% female) who were ≥0.5 years post TPIAT (median 4.1 years) and wearing Dexcom G6. Most patients had more than one HbA1c and corresponding CGM available (median 2 [IQR 1-4] per patient).

conclusionWe found that TIR 70-140 ≥ 50% and TIR 70-180 mg/dL ≥ 75% may be reasonable minimum targets for patients and providers using CGM data to manage diabetes long-term after TPIAT. Failure to meet these targets should prompt starting or adjusting insulin therapy, especially if hypoglycemia is not a concern.

Indexed as

BiomarkersBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HyperglycemiaIslets of Langerhans TransplantationPancreatectomyAdultContinuous Glucose MonitoringFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMiddle AgedBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanautologousblood glucoseclinical targetscontinuous glucose monitoring (CGM)diabetesglycated hemoglobinpancreatectomytotal pancreatectomy with islet autotransplantation (TPIAT)transplantation

Identifiers

PMID40454809
PMCPMC12128694

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.